Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib)

Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib) - Study to immuneresponse in patients treated with a tki

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32710

Enrollment

Registered

2008-10-16

Start date

2008-10-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GIST GIST kidney cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks, or patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed) - Patients who are indicated for influenza vaccination and and have been summoned for this vaccination by their GP - age >=18 years - signed Informed Consent Form -

Exclusion criteria

Exclusion criteria: - patients with an identified immunodeficiency disorder - patients that have been treated with corticosteroids in the past 2 weeks or who are still using these (except for a short period

Design outcomes

Primary

Measure	Time frame
cellular and humoral immune response	—

Secondary

Measure	Time frame
times the influenzavirus occurs	—

Countries

Netherlands

Outcome results